Literature DB >> 18544003

Variability in the diagnosis and management of patients with Alzheimer's disease and cerebrovascular disease: results from the GALATEA multicentre, observational study.

Pedro Gil1, José Luis Dobato Ayuso, José Manuel Marey, Manuel Antón, Carlos Guzmán Quilo.   

Abstract

BACKGROUND AND OBJECTIVES: There is frequently a degree of variability among different types of dementia specialists in clinical practice in both the clinical diagnosis and the management of patients with Alzheimer's disease and cerebrovascular disease (CVD). This variability may have an adverse effect on the use of medical resources as well as on patients' well-being. The main objective of this study was to describe the current diagnosis and management of patients with Alzheimer's disease and CVD in Spain. Other objectives were to determine whether there were significant differences in the diagnosis and management of these patients depending on physician characteristics and/or patient profile.
METHODS: This was an epidemiological, cross-sectional, multicentre study in which 107 physicians participated and recruited patients with Alzheimer's disease and CVD. During a 1-month period, physicians collected data on diagnosis, treatment, follow-up, adverse events and other characteristics of these patients. This study was performed under naturalistic conditions, and no restrictions were imposed on the physicians.
RESULTS: Physicians were mainly neurologists (76%), geriatricians (14%) and psychiatrists (8%) with a median age of 42 years. A total of 720 patients with a diagnosis of Alzheimer's disease and CVD were recruited. The median age of the patients was 78 years. Almost all patients were diagnosed by neuroimaging (98%) together with medical history (87%). The existence of a previous stroke coincident with cognitive deterioration was used as a diagnostic method in only 27% of patients. Among non-pharmacological treatment measures, diet was the most frequently recommended (61%), followed by cognitive stimulation (50%) and physical exercise (44%). The most commonly used pharmacological treatments were galantamine (59%), donepezil (14%) and rivastigmine (11%). The incidence of adverse events was low (3%), and all were considered non-severe. There were no significant correlations between physician age or physician years of practice and the diagnostic method used. The diagnostic method most frequently used by psychiatrists (100%) and geriatricians (97%) was medical history whereas this method was not used as much by neurologists (85%) [p = 0.0150]. Neuroimaging methods were more frequently used by neurologists (99%) and geriatricians (96%) compared with psychiatrists (84%) [p < 0.0001]. Patients with attention disorders had a higher frequency of follow-up visits (p = 0.0145) and were treated less frequently with donepezil (p = 0.0118).
CONCLUSIONS: Several possible areas of improvement in the management of patients with Alzheimer's disease and CVD were identified. These included better control of cardiovascular risk factors, such as hypertension and hyperlipidaemia, which have a high prevalence in this population, as has been shown in the present study. These potentially modifiable risk factors may assist in the prevention of Alzheimer's disease. Also identified was the need to emphasize the role of general practitioners in decreasing the time to diagnosis of Alzheimer's disease. Development of well designed clinical practice guidelines may help physicians decide on the most appropriate ways of diagnosing and managing patients with Alzheimer's disease and CVD and reduce practice variations between different medical specialities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544003     DOI: 10.2165/00044011-200828070-00004

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  35 in total

Review 1.  Vascular dementia as a frontal subcortical system dysfunction.

Authors:  J C Looi; P S Sachdev
Journal:  Psychol Med       Date:  2000-09       Impact factor: 7.723

Review 2.  Update on hypertension and Alzheimer's disease.

Authors:  Ingmar Skoog; Deborah Gustafson
Journal:  Neurol Res       Date:  2006-09       Impact factor: 2.448

Review 3.  [Epidemiology of Alzheimer's disease].

Authors:  Carole Dufouil; Annick Alpérovitch
Journal:  Rev Prat       Date:  2005-11-15

Review 4.  Should we screen for Alzheimer's disease? A review of the evidence for and against screening Alzheimer's disease in primary care practice.

Authors:  Paul R Solomon; Cynthia A Murphy
Journal:  Geriatrics       Date:  2005-11

Review 5.  Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.

Authors:  Ramón Cacabelos
Journal:  Methods Find Exp Clin Pharmacol       Date:  2007-07

Review 6.  Will a healthy lifestyle help prevent Alzheimer's disease?

Authors:  Sandra K Pope; Valorie M Shue; Cornelia Beck
Journal:  Annu Rev Public Health       Date:  2001-11-06       Impact factor: 21.981

7.  Mixed dementia: Alzheimer's and cerebrovascular disease.

Authors:  Kenneth Rockwood
Journal:  Int Psychogeriatr       Date:  2003       Impact factor: 3.878

Review 8.  Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development.

Authors:  Megan L Kerr; David H Small
Journal:  J Neurosci Res       Date:  2005-04-15       Impact factor: 4.164

Review 9.  Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications.

Authors:  Ramón Cacabelos; Lucía Fernández-Novoa; Valter Lombardi; Lola Corzo; Victor Pichel; Yasuhiko Kubota
Journal:  Neurol Res       Date:  2003-09       Impact factor: 2.448

Review 10.  Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia.

Authors:  L Clare; R T Woods; E D Moniz Cook; M Orrell; A Spector
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  3 in total

1.  Alzheimer's disease with vascular component: a distinct clinical entity?

Authors:  Javier Olazarán; Eloísa Navarro; José Manuel Rojo
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2012-09-22

2.  Persistence of cholinesterase inhibitor treatment in dementia: insights from a naturalistic study.

Authors:  Javier Olazarán; Eloísa Navarro; José Manuel Rojo
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2013-03-01

3.  Cognitive rehabilitation: Literature review based on levels of evidence.

Authors:  Patricia Regina Manzine; Sofia Cristina Iost Pavarini
Journal:  Dement Neuropsychol       Date:  2009 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.